Suchergebnisse - "Itolizumab"

PubPharm (16)

1

New Targeted Therapies for Uncontrolled Asthma

enthalten in: The journal of allergy and clinical immunology. In practice | 2019

von Corren, J.

2

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis : A network meta-analysis

enthalten in: Journal of pharmacological sciences | 2019

von Xu, G. | Xia, M. | Jiang, C. | +4

3

Clinical and experimental evidence for targeting CD6 in immune-based disorders

enthalten in: Autoimmunity reviews | 2018

von Consuegra-Fernández, M. | Lin, F. | Fox, D. | +1

4

The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients : results from a 6-month, open-label Phase I clinical trial

enthalten in: Clinical and experimental immunology | 2018

von Rodríguez, P. | Prada, D. | Moreno, E. | +15

5

Itolizumab in Psoriasis

enthalten in: Indian journal of dermatology | 2017

von Srivastava, A.

6

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis

enthalten in: Indian dermatology online journal | 2017

von Parthasaradhi, A. | Singh, V. | Parasramani, S. | +4

7

Itolizumab, a novel anti-CD6 monoclonal antibody : a safe and efficacious biologic agent for management of psoriasis

enthalten in: Expert opinion on biological therapy | 2017

von Dogra, S. | Uprety, S. | Suresh, S.

8

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab

enthalten in: PloS one | 2017

von Bughani, U. | Saha, A. | Kuriakose, A. | +11

ErratumIn: PLoS One. 2018 Jan 30;13(1):e0192335. - PMID 29381749

9

Commentary : CD6 As a Potential Target for Treating Multiple Sclerosis

enthalten in: Frontiers in immunology | 2017

von Consuegra-Fernández, M. | Isamat, M. | Lozano, F.

CommentOn: Proc Natl Acad Sci U S A. 2017 Mar 7;114(10 ):2687-2692. - PMID 28209777

10

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis : safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study

enthalten in: Clinical rheumatology | 2016

von Chopra, A. | Chandrashekara, S. | Iyer, R. | +10